Eric Jay Small
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cancer Research top 0.05%
- Cancer, Lipids, and Metabolism
Papers in
-
- Prostate Cancer Treatment and Research 222
- Prostate Cancer Diagnosis and Treatment 65
- Renal cell carcinoma treatment 26
- Oncology 81
- Cancer Immunotherapy and Biomarkers 29
- Co-authors
- Susan Halabi (76 shared papers)Philip W. Kantoff (37 shared papers)Celestia S. Higano (27 shared papers)Brian I. Rini (36 shared papers)Paul F. Schellhammer (7 shared papers)Nicholas J. Vogelzang (38 shared papers)Mark Walter Frohlich (8 shared papers)Charles H. Redfern (3 shared papers)
- Journals
- Journal of Clinical Oncology (61 papers)Cancer (42 papers)The Journal of Urology (36 papers)Annals of Oncology (23 papers)Clinical Cancer Research (22 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Eric Jay Small
413 papers receiving 35.8k citations
Eric Jay Small's Hit Papers
Peers
Comparison fields: 5 of 154
- Pulmonary and Respiratory Medicine 21.6k
- Cancer Research 6.2k
- Oncology 11.2k
- Immunology 6.2k
- Radiology, Nuclear Medicine and Imaging 3.9k
Countries citing papers authored by Eric Jay Small
This map shows the geographic impact of Eric Jay Small's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Jay Small with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Jay Small more than expected).
Fields of papers citing papers by Eric Jay Small
This network shows the impact of papers produced by Eric Jay Small. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Jay Small. The network helps show where Eric Jay Small may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Jay Small, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 421 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer Hit paper breakdown → | 2010 | 4435 |
| 2 | Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer Hit paper breakdown → | 2004 | 3003 |
| 3 | Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Hit paper breakdown → | 2008 | 1770 |
| 4 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Hit paper breakdown → | 2018 | 953 |
| 5 | Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer Hit paper breakdown → | 2006 | 903 |
| 6 | Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Hit paper breakdown → | 2008 | 744 |
| 7 | Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer Hit paper breakdown → | 2009 | 654 |
| 8 | Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206 Hit paper breakdown → | 2010 | 634 |
| 9 | Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer Hit paper breakdown → | 2003 | 561 |
| 10 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Hit paper breakdown → | 2017 | 553 |
| 11 | 2000 | 526 | |
| 12 | Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial Hit paper breakdown → | 2002 | 512 |
| 13 | Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. | 1999 | 494 |
| 14 | 2004 | 409 | |
| 15 | 2005 | 399 | |
| 16 | Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer Hit paper breakdown → | 2015 | 386 |
| 17 | 2006 | 383 | |
| 18 | Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401 Hit paper breakdown → | 2012 | 375 |
| 19 | Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2014 | 364 |
| 20 | 2007 | 347 |
About Eric Jay Small
Eric Jay Small is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 421 papers that have together received 37.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (222 papers), Prostate Cancer Diagnosis and Treatment (65 papers), Cancer, Lipids, and Metabolism (39 papers), Radiopharmaceutical Chemistry and Applications (35 papers), Immunotherapy and Immune Responses (33 papers), Cancer Immunotherapy and Biomarkers (29 papers), Renal cell carcinoma treatment (26 papers) and Hormonal and reproductive studies (20 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (21.6k citations), Cancer Research (6.2k citations), Oncology (11.2k citations), Immunology (6.2k citations) and Radiology, Nuclear Medicine and Imaging (3.9k citations). Eric Jay Small has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Susan Halabi, Philip W. Kantoff, Celestia S. Higano, Brian I. Rini, Paul F. Schellhammer, Nicholas J. Vogelzang, Mark Walter Frohlich, Charles H. Redfern, R. Dreicer and Lawrence H. Fong. Their work appears in journals such as Journal of Clinical Oncology, Cancer, The Journal of Urology, Annals of Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.